Vertex stands by Orkambi, Kalydeco guidance

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported modest upticks in 2Q16 sales of cystic fibrosis drugs Orkambi ivacaftor/lumacaftor and Kalydeco ivacaftor.

The biotech reported $245.5 million in global sales of Orkambi, narrowly missing the consensus estimate of $249 million. Orkambi sales were $223.1 million in 1Q16. The drug was launched in July 2015. ...